XML 31 R14.htm IDEA: XBRL DOCUMENT
v3.8.0.1

GOODWILL AND OTHER INTANGIBLE ASSETS, NET | 12 Months Ended
--- | ---
Dec. 31, 2017
Goodwill And Intangible Assets Disclosure [Abstract] |
GOODWILL AND OTHER INTANGIBLE ASSETS, NET | NOTE 6 GOODWILL AND OTHER INTANGIBLE ASSETS, NET Goodwill The following table is a summary of the activity in goodwill by segment.
(in millions) |  | Americas |  |  | EMEA |  |  | APAC |  |  | Total |
December 31, 2015 |  | $ | 2,144 |  |  | $ | 341 |  |  | $ | 202 |  |  | $ | 2,687 |
Additions |  |  | 3 |  |  |  | — |  |  |  | — |  |  | $ | 3 |
Currency translation and other adjustments |  |  | (76 | ) |  |  | (12 | ) |  |  | (7 | ) |  | $ | (95 | )
December 31, 2016 |  | $ | 2,071 |  |  | $ | 329 |  |  | $ | 195 |  |  | $ | 2,595 |
Additions |  |  | 242 |  |  |  | 38 |  |  |  | 23 |  |  |  | 303 |
Currency translation and other adjustments |  |  | 161 |  |  |  | 25 |  |  |  | 15 |  |  |  | 201 |
December 31, 2017 |  | $ | 2,474 |  |  | $ | 392 |  |  | $ | 233 |  |  | $ | 3,099 |
As of December 31, 2017, there were no reductions in goodwill relating to impairment losses. As discussed in Note 17 – Segment Information, in 2017, Baxter announced a change in its commercial structure to improve performance, optimize costs, increase speed in the decision-making process and drive improved accountability across the company. This resulted in a change in the company’s operating segments and reporting units. The company allocated goodwill to its new reporting units using a relative fair value approach. In addition, the company completed an assessment of any potential goodwill impairment for all reporting units immediately prior to and after the reallocation and determined that no impairment existed. Other Intangible Assets, Net The following table is a summary of the company’s other intangible assets.
(in millions) |  | Developed technology, including patents |  |  | Other amortized intangible assets |  |  | Indefinite-lived intangible assets |  |  | Total |
December 31, 2017 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gross other intangible assets |  | $ | 2,002 |  |  | $ | 435 |  |  | $ | 172 |  |  | $ | 2,609 |
Accumulated amortization |  |  | (1,010 | ) |  |  | (225 | ) |  |  | — |  |  |  | (1,235 | )
Other intangible assets, net |  | $ | 992 |  |  | $ | 210 |  |  | $ | 172 |  |  | $ | 1,374 |
December 31, 2016 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gross other intangible assets |  | $ | 1,690 |  |  | $ | 384 |  |  | $ | 57 |  |  | $ | 2,131 |
Accumulated amortization |  |  | (855 | ) |  |  | (165 | ) |  |  | — |  |  |  | (1,020 | )
Other intangible assets, net |  | $ | 835 |  |  | $ | 219 |  |  | $ | 57 |  |  | $ | 1,111 |
Intangible asset amortization expense was $154 million in 2017, $163 million in 2016, and $158 million in 2015. The anticipated annual amortization expense for definite-lived intangible assets recorded as of December 31, 2017 is $163 million in 2018, $158 million in 2019, $152 million in 2020, $147 million in 2021 and $145 million in 2022. In 2016, the company recorded an impairment charge of $27 million related to an indefinite-lived intangible asset (acquired IPR&D) relating to its in-center hemodialysis program. The asset was written down to estimated fair value and recorded in R&D expenses. Additionally, the company recorded an impairment charge of $51 million, of which $41 million was related to a developed technology asset, relating to the company’s synthetic bone repair products business which was acquired from ApaTech Limited in 2010. The assets of the business were written down to estimated fair value and the impairment charge was recorded in cost of sales. In 2015, the company recorded impairments of approximately $10 million related to acquired IPR&D and $13 million related to developed technology.

X
- References No definition available. + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -URI http://asc.fasb.org/topic&trid=2144416 + Details
Name: | us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration